Murex Announces Joint Development Agreement with GNS
News Jun 05, 2006
Murex Pharmaceuticals has announced its joint agreement with Gene Network Sciences (GNS) to develop cancer therapeutics.
Murex will utilize technology from GNS to create computer-based models that enhance identification and validation of cancer targets.
These computer models identify genes unique to an individual's malignancy. Murex identifies key alterations in cancer cells that dictate malignant growth.
GNS technology is integral in predicting which pathways are most significant in a patient's cancer. Murex then designs shRNA based vaccines to stop the cancer growth.
"We are very pleased to formalize our joint development agreement with Gene Network Sciences," said David Shanahan, president and CEO of Murex Pharmaceuticals.
"Together, we have proven the value of this technology and now move to integrate GNS into our development systems."
"We further expect that utilization of these 'in silico' inference models will enhance both the safety and efficacy of our products."
Murex Pharmaceuticals develops individualized cancer therapies using proprietary molecular analytics.
The integration of GNS technology, which uses computer models to study cancer therapies, brings unique insight to the complex interactions of these cellular processes.
"This marks the first time that biosimulation will be integral to the synthesis of therapies for cancer patients based on their individual gene expression data," said Colin Hill, CEO of Gene Network Sciences.
GNS scientists will work directly with Murex teams at Murex research and development facilities located in Dallas and Carrollton, Texas.
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE